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with XPD312 AspAsp (36.4 m) than for 27 p with Asn variants (9.8 
m) (P=0.009); MS in this group of younger p was 45.4 m for AspAsp 
vs 15.8 m for Asn (P=0.04). No other signiﬁcant correlation between 
SNPs and survival was observed (Table). 
Conclusions: Interaction between SNPs, age and risk of lung cancer 
has previously been described. XPD312 AspAsp in p <59 y predicts 
longer survival in stage IIIA (N2) and IIIB NSCLC treated with neoad-
juvant chemotherapy.
  EFS   MS  
 N m (95% CI) P N m (95% CI) P
XPD 751   0.13   0.15
LysLys 45 13.22 (3.49-22.95)  45 32.14 (5.08-59.20)  
LysGln& 
GlnGln 64 8.82 (6.11-11.52)  64 14.90 (10.39- 19.41)  
XPD312   0.03   0.05
AspAsp 55 13.98 (4.79 - 23.17)  55 32.14 (7.58-56.70)  
AspAsn& 
AsnAsn 54 7.34 (4.53-10.14)  54 12.04 (6.09-17.99)  
RRM1-37   0.87   0.53
CC 59 9.11 (6.03-12.09)  59 14.97 (4.61-25.32)  
CA & AA 49 10.79 (8.22- 13.36)  49 16.84 (1.50-32.18)  
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Background: BIBF 1120 is an orally available, highly potent triple 
angiokinase inhibitor (VEGFRs, PDGFRs, FGFRs) that inhibits tumor 
growth through mechanisms suppressing tumor neovascularization. 
This Phase I, open-label dose escalation study investigated the combi-
nation of BIBF 1120 together with carboplatin and paclitaxel in previ-
ously untreated patients with advanced stage (IIIB/IV) NSCLC. The 
primary objectives of this trial were to determine the safety, tolerability, 
and maximum tolerated dose (MTD) of BIBF 1120 in combination 
with carboplatin and paclitaxel.
Methods: Untreated patients with advanced stage NSCLC, PS 0-1 
were eligible for this trial. Patients with squamous cell histology were 
eligible, but patients with cavitary or necrotic tumors or those with ra-
diologic evidence of great vessel invasion were excluded. The trial was 
an open label, dose escalation design with BIBF 1120 (starting dose 50 
mg bid) taken on days 2-21, combined with carboplatin (AUC=6) and 
paclitaxel (200 mg/m2) on day 1 of each 21 day cycle. Patients could 
be treated for a minimum of four and a maximum of six cycles of com-
bination therapy, with an option for BIBF 1120 monotherapy following 
completion of planned combination therapy. BIBF 1120 was escalated 
at doses of 50 mg per cohort until the MTD dose was determined. MTD 
was deﬁned as the dose of BIBF 1120 that at which two or more out of 
six patients experienced dose limiting toxicity (DLT) in the ﬁrst treat-
ment cycle. Tumor assessments were performed at screening and after 
every second treatment cycle according to RECIST.
Results: Twenty-ﬁve patients (18 females and 7 males) in total and 14 
at the MTD were treated in this study. The MTD dose of BIBF 1120 
was determined to be 200 mg bid in combination with carboplatin and 
paclitaxel and the combination of BIBF 1120 with this doublet was 
well tolerated. Five DLT events occurred in the ﬁrst treatment cycle 
for all doses including elevations in liver enzymes (2/5), thrombocy-
topenia (1/5), abdominal pain (1/5), and rash (1/5) and resolved after 
discontinuation of study medication. Ten patients received BIBF 1120 
monotherapy after completing their planned combination therapy (2 to 
6 additional cycles). Best responses by RECIST (17 patients evaluable 
for response) include 7 partial responses (PR) and 10 patients with 
stable disease (SD). 
Conclusions: The combination of BIBF 1120 together with carboplatin 
and paclitaxel in previously untreated patients with advanced NSCLC 
as shown to be safe and well-tolerated in this study. The MTD dose of 
BIBF 1120 was 200 mg bid when given with carboplatin and paclitaxel 
every three weeks. Initial signs of clinical efﬁcacy were observed in the 
small number of patients treated in this trial.
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small-cell lung cancer: preliminary experience from an expanded 
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Background: Erlotinib (Tarceva) is an orally active, selective EGFR 
inhibitor. In a large, phase III trial (BR.21) second- or third-line 
erlotinib monotherapy (150mg/day) signiﬁcantly prolonged survival in 
patients with advanced non-small-cell lung cancer (NSCLC). The erlo-
tinib expanded access programme ( TRUST ) was designed to evaluate 
the safety and efﬁcacy of erlotinib and has enabled more than 11500 
patients worldwide to receive erlotinb treatment. This paper reports the 
preliminary outcome of erlotinib treatment in Chinese patients who en-
rolled into the EAP at Cancer Institute/ Hospital, Chinese Academy of 
Medical Sciences(CAMS) & Peking Union Medical College(PUMC).
Methods: Patients with stage IIIB / IV NSCLC, with performance 
status from 0 to 3, were eligible if they had received one or two prior 
platinum-based chemotherapy regimens. Patients received oral erlotinib 
(150mg/day) until unacceptable toxicity or disease progression.Dose 
interruption or dose reduction (to 100mg then 50mg) was permitted for 
treatment-related AEs. 
Results: The median age of the 45 patients who underwent ran-
domization was 54.9(28-74 ) years. Baseline characteristics (% 
of patients) were:male/female:69/31;ECOG performance status 
0/1/2/3:18/58/15/9;stage IIIB / IV:80/20;non-smoker/former or 
current smoker:69/31;ademocarcinoma/squamous cell carcinoma 
67/20;erlotinib as second-line/third-line treatment: 69/31.Safety and 
efﬁcacy data were available for 42 patients. Erlotinib-ralated ad-
verse events (AEs) were generally mild (grade1 and 2 assessed using 
CTCAE 3.0) and reversible. The most frequent AEs were acneform 
rash (76%),diarrhea(55%),and elevated indirect serum bilirubin 
levels(50%). Grade 3 AE was elevation of alanine aminotransferase 
(ALT,5%).No patients withdrew because of erlotinib-related event. One 
patient had a dose reduction to 100 mg, due to abnormal hepatic func-
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tion. The best response rate was 21.4% partial response (PR) and 29% 
stable disease (SD) according to RECIST (disease control rate 50%). 
With a median follow-up time of 6.1 months, the six-month survival 
rate was 77.5%,and the median time to progression was 84 days.76% of 
patients had improvement in symptoms after taking erlotinib.
Conclusion: Erlotinib demonstrated clinically signiﬁcant antitumor 
activity and favourable tolerability as monotherapy in this series of 
Chinese patients with advanced NSCLC and was also associated with 
remarkable symptom relief .
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Background: Epidermal growth factor receptor has been extensively 
studied as a target of therapy in the NSCLC. Geﬁtinib and erlotinib are 
the tyrosine kinase inhibitors (TKI’s) of EFGR. The two drugs show 
similar chemical structure and mechanism but differ in phamatokinetics 
(higher AUC in erlotinib). Despite early dramatic and durable respons-
es in some patients, the majority of these patients eventually develop 
disease progression after initial response to these agents. The activity 
of erlotinib in patients who had disease progression following geﬁtinib 
treatment is unknown. 
Material and Methods: Patients with NSCLC who had treatment with 
erlotinib (150mg/day) after progression on geﬁtinib (250mg/daily) 
were analyzed. 
Result: A total of 19 patients who had advanced or recurred NSCLC, 
14 patients were evaluable for response but 5 patients did not have an 
evaluable lesion or sufﬁcient treatment duration for response evaluation 
(due to adverse effect or follow up loss). 12 patients were female and 
2 were male. Patients’ age ranged from 34 to 76 (median 53). 1 patient 
was a smoker, the others were a never-smoker. The histologic type was 
adenocarcinoma (n=13), bronchioloalveolar carcinoma (n=1). Prior 
best overall response to geﬁtinib was PR 42%, SD 29% and PD 29%. 
12 patients were treated with erlotinib as a 3rd or 4th line therapy after 
geﬁtinib and the others were treated as from 6th to 7th line chemother-
apy. One patient showed a partial response (7%), another patient stable 
disease (7%), and the others disease progression (86%). The patients 
with PR or SD were female and never-smoker. The prior response to 
geﬁtinib was SD in these two patients. The pathologic type was adeno-
carcinoma in patient with PR, and bronchioloalveolar carcinoma in pa-
tient with SD. According to prior overall response to geﬁtinib, median 
time to progression of erlotinib was 0.8 months (95% CI 0.64-0.96) in 
PD, 0.93 months (95% CI 0.73-1.13) in PR and 2.1 months (95% CI 
0.69-3.51) in SD (p=0.14).
Conclusion: This result suggests that the activity of erlotinib after 
progression on geﬁtinib is limited. Further investigation for mechanism 
of resistance and 2nd response to TKI is needed.
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Background: Although the epidermal growth factor receptor (EGFR) 
has emerged as a promising target for patients with EGFR overexpress-
ing non-small cell lung cancer, the impetus to standardize for their 
prognostic and predictive value is still much needed. In this study, we 
performed a study to establish a relationship among EGFR mutation, 
EGFR gene copy, and responses for geﬁtinib therapy in patients with 
lung adenocarcinoma. 
Methods: The EGFR status was evaluated by direct DNA sequencing 
of exons 18, 19, and 21 and ﬂuorescence in situ hybridization (FISH) 
in 284 patients, and the clinical data including geﬁtinib treatment were 
gathered. 
Results: Among 284 biopsy tumor samples, which were more than 
0.1 cm, EGFR mutation with lung adenocarcinoma, mutation analysis 
was possible in 263 cases (92.4%) and gene ampliﬁcation analysis was 
possible in 270 cases (95.1%). Male:female ratio was 44.4%:55.6% and 
median age was 58 (range, 21-84). One hundred and eighteen patients 
(44.9%) had EGFR mutations and 30 patients (11.1%) had EGFR gene 
ampliﬁcations. The mutations included deletion or mutation of exon 
19 in 65 patients (55.1%), mutation of exon 21 in 43 patients (36.4%) 
and mutation of exon 18 in 10 patients (8.5%). Of 172 non-smoking pa-
tients, 92 patients (53.5%) had EGFR mutations in contrast to 26 of 91 
(28.6%) in smoking patients. Of 177 non-smoking patients, 24 patients 
(13.6%) had EGFR gene ampliﬁcation in contrast to 6 of 93 (6.5%) in 
smoking patients. Of 30 patients with EGFR gene ampliﬁcation, 27 
patients (90%) harbored EGFR mutation simultaneously. One hundred 
and twenty-two patients were treated with geﬁtinib and 84 patients had 
measurable lesion. In the patients with measurable lesion, response 
rate in patients with EGFR mutation was 69.7% (23 of 33 patients), 
in contrast to 24.4% (10 of 41 patients) in patients without mutation. 
The response rate in the patients with EGFR gene ampliﬁcation was 
83.3% (5 of 6 patients). Of the patients treated with geﬁtinib, ﬁfty 
eight patients with EGFR mutation had signiﬁcantly prolonged time to 
progression (TTP) than 50 patients without mutation (median survival, 
13.1 vs. 2.6 months; p = .0003). Of 58 patients with EGFR mutation, 
13 patients with simultaneous EGFR gene ampliﬁcation showed much 
longer TTP (median survival time not reached).
Conclusions: EGFR mutation and EGFR gene ampliﬁcation could be 
tested with small sized biopsy sample. We showed its clinical impor-
tance with regard to geﬁtinib. Lung adenocarcinoma that harbored 
EGFR mutation and gene ampliﬁcation simultaneously showed better 
tumor response and TTP with geﬁtinib.
